Alexandra J Spencer
Overview
Explore the profile of Alexandra J Spencer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arunachalam P, Ha N, Dennison S, Spreng R, Seaton K, Xiao P, et al.
Sci Transl Med
. 2024 Jul;
16(758):eadn6605.
PMID: 39083589
Authorization of the Matrix-M (MM)-adjuvanted R21 vaccine by three countries and its subsequent endorsement by the World Health Organization for malaria prevention in children are a milestone in the fight...
2.
Bissett C, Belij-Rammerstorfer S, Ulaszewska M, Smith H, Kailath R, Morris S, et al.
NPJ Vaccines
. 2024 Jun;
9(1):118.
PMID: 38926455
Although licensed vaccines against influenza virus have been successful in reducing pathogen-mediated disease, they have been less effective at preventing viral infection of the airways and current seasonal updates to...
3.
Flaxman A, Sebastian S, Appelberg S, Cha K, Ulaszewska M, Purushotham J, et al.
PLoS Pathog
. 2024 Jun;
20(6):e1012262.
PMID: 38924060
Viral haemorrhagic fevers (VHF) pose a significant threat to human health. In recent years, VHF outbreaks caused by Ebola, Marburg and Lassa viruses have caused substantial morbidity and mortality in...
4.
Lv X, Martin J, Hoover H, Joshi B, Wilkens M, Ullisch D, et al.
iScience
. 2024 Feb;
27(3):109006.
PMID: 38361610
Many vaccines, including those using recombinant antigen subunits, rely on adjuvant(s) to enhance the efficacy of the host immune responses. Among the few adjuvants clinically approved, QS-21, a saponin-based immunomodulatory...
5.
Speck P, Mackenzie J, Bull R, Slobedman B, Drummer H, Fraser J, et al.
mBio
. 2023 Apr;
14(3):e0081523.
PMID: 37097032
No abstract available.
6.
Speck P, Mackenzie J, Bull R, Slobedman B, Drummer H, Fraser J, et al.
mSphere
. 2023 Apr;
8(3):e0016523.
PMID: 37097028
No abstract available.
7.
Speck P, Mackenzie J, Bull R, Slobedman B, Drummer H, Fraser J, et al.
J Virol
. 2023 Apr;
97(5):e0045123.
PMID: 37097023
No abstract available.
8.
Foster W, Newman J, Thakur N, Spencer A, Davies S, Woods D, et al.
Immunol Cell Biol
. 2023 Mar;
101(6):479-488.
PMID: 36975169
Effective vaccines have reduced the morbidity and mortality caused by severe acute respiratory syndrome coronavirus-2 infection; however, the elderly remain the most at risk. Understanding how vaccines generate protective immunity...
9.
Saunders J, Gilbride C, Dowall S, Morris S, Ulaszewska M, Spencer A, et al.
EBioMedicine
. 2023 Mar;
90:104523.
PMID: 36933409
Background: The tick-borne bunyavirus, Crimean-Congo Haemorrhagic Fever virus (CCHFV), can cause severe febrile illness in humans and has a wide geographic range that continues to expand due to tick migration....
10.
Foster W, Lee J, Thakur N, Newman J, Spencer A, Davies S, et al.
Cell Rep Med
. 2022 Dec;
3(12):100845.
PMID: 36455555
Emergence from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been facilitated by the rollout of effective vaccines. Successful vaccines generate high-affinity plasma blasts and long-lived protective memory...